Ownership and insider activity for TransCode Therapeutics, Inc. (RNAZ): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers.
Price
| Price | $1.68 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-09 | Fitzgerald Thomas A | A-Award | 185,000 | $329K |
| 2026-08-03 | DEFJ, LLC | C-Conversion | 2,020,582 | $202 |
| 2026-08-03 | DEFJ, LLC | C-Conversion | 11,813,859 | $1K |
| 2026-08-03 | DEFJ, LLC | C-Conversion | 1,181 | |
| 2026-08-03 | DEFJ, LLC | C-Conversion | 202 | |
| 2026-07-27 | DEFJ, LLC | |||
| 2026-07-27 | DEFJ, LLC | 11,813,859 | ||
| 2026-07-27 | DEFJ, LLC | 2,020,582 | ||
| 2025-10-06 | CZEREPAK ELIZABETH | |||
| 2025-12-19 | STOVER JACK E |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $212979 | $204471 | $828016 | $20.8M | $5.0M | $2.8M | $5.8M | $17.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | $360229 | 0 | 0 | $3.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $214646 | $204471 | $831215 | $22.7M | $7.4M | $4.5M | $7.1M | $22.0M |
| Property, Plant & Equipment | 0 | 0 | 0 | $206268 | $208581 | $602401 | $89305 | $370681 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $25.7M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $114.3M |
| Total Assets | $214646 | $216743 | $1.1M | $22.9M | $7.6M | $5.2M | $7.3M | $162.4M |
| Accounts Payable | 0 | $27257 | 0 | $2.0M | 0 | 0 | $2.6M | $3.1M |
| Short-term Debt | $35685 | 0 | 0 | 0 | 0 | 0 | $38291 | 0 |
| Total Current Liabilities | $117682 | $62942 | $404862 | $2.5M | $4.3M | $3.5M | $2.8M | $3.5M |
| Long-term Debt | $436215 | $927810 | $2.1M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $718613 | $1.3M | $4.5M | $2.5M | $4.3M | $3.5M | $9.3M | $152.1M |
| Retained Earnings | -$510777 | -$1.1M | -$3.5M | -$10.3M | -$27.9M | -$46.4M | -$63.2M | -$97.9M |
| Total Equity | -$503967 | -$1.1M | -$3.4M | $20.4M | $3.2M | $1.6M | -$2.0M | $10.3M |
| Total Debt | $471900 | $927810 | $2.1M | 0 | 0 | $450571 | $38291 | 0 |
| Net Debt | $258921 | $723339 | $1.3M | -$20.8M | -$5.0M | -$2.3M | -$5.8M | -$17.8M |
| Working Capital | $96964 | $141529 | $426353 | $20.2M | $3.0M | $964848 | $4.3M | $18.5M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.97 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -1.26 |
Profitability
| Return on Equity | -58.08% |
| Return on Invested Capital | -23.73% |
| Return on Assets | -28.33% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · APRE · APVO · BOLT · GLTO · HCWB · INAB
Explore sector: Healthcare · Biotechnology
More sections of RNAZ: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks